| Cardiac saphenous vein bypass graft disease. | |
| | |
MedLine Citation:
|
PMID: 15478036 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Coronary artery bypass grafting is an effective treatment for myocardial ischaemia and is particularly important in patients with multivessel disease and diabetes. However, up to 40% of saphenous vein grafts will occlude within 10 years of surgery. The predominant mechanisms for saphenous vein graft disease are thrombosis, intimal hyperplasia, and accelerated atherosclerosis. The pathology of these changes and the role of key factors such as nitric oxide, cellular proliferation, and the role of hypercholesterolemia and hypertriglyceridaemia, are reviewed. Saphenous vein graft disease is among the first cardiovascular conditions to show significant benefit from gene therapy and promises to show remarkable developments in the near future. |
| | |
Authors:
|
G T Lau; H C Lowe; L Kritharides |
Related Documents
:
|
332366 - Morphologic observations in biologic conduits between aorta and coronary artery. 11565046 - The case for an in situ lesser saphenous vein bypass. 8903266 - Aortocoronary bypass with saphenous vein graft. seven-year follow-up. 1973. 8266266 - The continuing challenge of aneurysms of the popliteal artery. 22683616 - Aortic stenosis: a contemporary review. 3238666 - Thoraco-pleural actinomycosis presenting like diffuse pulmonary embolism. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Seminars in vascular medicine Volume: 4 ISSN: 1528-9648 ISO Abbreviation: Semin Vasc Med Publication Date: 2004 May |
Date Detail:
|
Created Date: 2004-10-12 Completed Date: 2005-02-08 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100940307 Medline TA: Semin Vasc Med Country: United States |
Other Details:
|
Languages: eng Pagination: 153-9 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Concord Repatriation General Hospital, Hospital Rd, Concord, NSW 2139, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Cell Proliferation Coronary Artery Bypass* Diabetic Angiopathies / physiopathology Graft Occlusion, Vascular / pathology, physiopathology* Humans Hyperlipidemias / physiopathology Nitric Oxide / physiology Risk Factors Saphenous Vein / pathology, transplantation* Vascular Endothelial Growth Factor A / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Vascular Endothelial Growth Factor A; 10102-43-9/Nitric Oxide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hypothyroidism and cardiovascular disease: role of new risk factors and coagulation parameters.
Next Document: Depressive disorders and the metabolic syndrome of insulin resistance.